1Byrne B, Crawford J, Bonner GJ, et al. Trends in chemotherapy use and survival for patients with metastatic non-small cell lung cancer [C]. ASCO,2004, 23: A707.
2Kubota K, Nishiwaki Y, Ohashi Y, et al. The Four-Arm Cooperative Study (FACS) for advanced non-small-cell lung cancer (NSCLC) [C]. ASCO,2004, 23: A 7006.
3Tester WJ, Stephenson P, Langer CJ, et al. ECOG 1599: Randomized phase Ⅱ study of paclitaxel/carboplatm or gemcitabine/cisplatin in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC) [C]. ASCO,2004, 23: A 7055.
4Barradas P, Costa A, Cristovao M, et al. What is the best drug in combination with a platinum-derivative in the treatment of advanced non-small cell lung cancer (NSCLC)? A gemcitabine (G)/vinorelbine (V) retrospective study B[C]. ASCO,2004, 23: A7295.
5Quadvlieg V,Bosquee L, Gustin M, et al. Frontline gemcitabine and cisplatin based chemotherapy in patients with NSCLC inoperable brain metastases[C]. ASCO,2004, 23: A 7117.
6Kosmidis PA, Dimopoulos MA, Syrigos C, et al. Gemcitabine (G) vs gemcitabine-carboplatin (GCB) for patients with advanced non-small cell lung cancer (NSCLC) and PS:2. A prospective randomized phase II study of the Hellenic Co-Operative Oncology Group[C]. ASCO,2004, 23: A 7058.
7Neubauer MA, Reynolds CH, Joppert M, et al. Preliminary results of a phase II trial utilizing gemcitabine in patients with advanced non-small cell lung cancer and a performance status[C]. ASCO,2004, 23: A 7121.
8Buosi R, Poletti S, Cantele V, et al. Preliminary results of phase II trial with combination of gemcitabine and oxaliplatin in elderly patients with advanced NSCLC[C]. ASCO,2004, 23: A 7348.
9Novello S, Barone C, Buosi R, et al. Early data of phase Ⅲ study in patients (pts) with stage IV non-small-cell lung cancer (NSCLC) treated with two cycles of cisplatin/gemcitabine followed by a randomization to three additional cycles of the same combination or gemcitabine alone[C]. ASCO,2004, 23: A 7069.
10Krzakowski M, Wenczl M, Brodowicz T, et al. Gemcitabine and cisplatin (GC) +/ - subsequent maintenance therapy with single-agent gemcitabine in advanced non-small cell lung cancer (NSCLC): Preliminary results of a randomized trial of the Central European Cooperative Oncology Group (CECOG)[C]. ASCO,2004, 23: A 7067.
